Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record

View original at finance.yahoo.com
Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record US stocks diverged on Tuesday, Tesla (TSLA) stock hitting a new record at the same time that the Dow and S&P 500 slumped as investors saw a mixed picture from updates on the labor market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Brent crude prices will slip into the $50s per barrel in 2026, potentially dropping into $40s or $30s if OPEC+ doesn't cut production

    80% confidence

  • The Amazon partnership renewal was largely in line with the current program and has been a win-win on both sides

    80% confidence

  • Bitcoin has been trading in a choppy range between 85k-94k with continued lack of interest and low volumes across crypto markets

    80% confidence

  • Brent crude prices will slip into the $50s per barrel in 2026, potentially dropping into $40s or $30s if production continues

    80% confidence

  • November jobs report data has a pretty big margin of error due to government shutdown and DOGE cuts, with revisions expected in January

    80% confidence

  • The Federal Reserve needs to be careful in assessing household survey data and look at it with a somewhat skeptical eye

    80% confidence

  • Pfizer faces challenges with no re-rating catalyst as company works through multi-year loss of exclusivity period until 2029

    80% confidence

  • Ukraine has secured a deal for US security guarantees in bid to end the war

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500 slip, Nasdaq snaps three-day losing streak as Tesla climbs to record — Source | Via News | Via News